Functional assays show that PON2 silencing, particularly via shRNA or CRISPR-Cas9, reduces proliferation, induces apoptosis, and sensitises tumour cells to chemotherapeutic agents (Wang et al. 2019; Pan et al. 2021). The gene discussed is PON2; the disease is neoplasm.